{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:01:26Z","timestamp":1762210886889},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T00:00:00Z","timestamp":1498089600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Pediatr"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s12519-017-0050-5","type":"journal-article","created":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T03:11:21Z","timestamp":1498187481000},"page":"472-478","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Performance of QuantiFERON\u00ae-TB Gold In-Tube assay in children receiving disease modifying anti-rheumatic drugs"],"prefix":"10.1007","volume":"13","author":[{"given":"Francesca","family":"Gabriele","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Trachana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Simitsopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Polixeni","family":"Pratsidou-Gertsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Iosifidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoi Dorothea","family":"Pana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Roilides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,22]]},"reference":[{"key":"50_CR1","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/BOR.0b013e3283474d62","volume":"23","author":"R Smith","year":"2011","unstructured":"Smith R, Cattamanchi A, Steingart KR, Denkinger C, Dheda K, Winthrop KL, et al. Interferon-\u03b3 release assays for diagnosis of latent tuberculosis infection: evidence in immune-mediated inflammatory disorders. Curr Opin Rheumatol 2011;23:377\u2013384.","journal-title":"Curr Opin Rheumatol"},{"key":"50_CR2","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1093\/cid\/cit489","volume":"57","author":"SS Toussi","year":"2013","unstructured":"Toussi SS, Pan N, Walters HM, Walsh TJ. Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-\u03b1 inhibitors: systematic review of the literature. Clin Infect Dis 2013;57:1318\u20131330.","journal-title":"Clin Infect Dis"},{"key":"50_CR3","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1183\/09031936.00028510","volume":"36","author":"I Solovic","year":"2010","unstructured":"Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010;36:1185\u20131206.","journal-title":"Eur Respir J"},{"key":"50_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1546-0096-12-45","volume":"12","author":"K Yasui","year":"2014","unstructured":"Yasui K. Immunity against Mycobacterium tuberculosis and the risk of biologic anti-TNF-\u03b1 reagents. Pediatr Rheumatol Online J 2014;12:45.","journal-title":"Pediatr Rheumatol Online J"},{"key":"50_CR5","first-page":"201","volume":"31","author":"J Gomez-Reino","year":"2006","unstructured":"Gomez-Reino J, Carmona L. Recommendations to lower the risk of tuberculosis in patients treated with tumour necrosis factor alpha antagonists. Acta Reumatol Port 2006;31:201\u2013203.","journal-title":"Acta Reumatol Port"},{"key":"50_CR6","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098\u20131104.","journal-title":"N Engl J Med"},{"key":"50_CR7","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/art.20009","volume":"50","author":"F Wolfe","year":"2004","unstructured":"Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004;50:372\u2013379.","journal-title":"Arthritis Rheum"},{"key":"50_CR8","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.autrev.2008.07.011","volume":"8","author":"A Lalvani","year":"2008","unstructured":"Lalvani A, Millington KA. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun Rev 2008;8:147\u2013152.","journal-title":"Autoimmun Rev"},{"key":"50_CR9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1183\/09031936.00115110","volume":"37","author":"R Diel","year":"2011","unstructured":"Diel R, Goletti D, Ferrara G, Bothamley G, Cirillo D, Kampmann B, et al. Interferon-\u03b3 release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011;37:88\u201399.","journal-title":"Eur Respir J"},{"key":"50_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1136\/archdischild-2013-303641","volume":"98","author":"L Pollock","year":"2013","unstructured":"Pollock L, Basu Roy R, Kampmann B. How to use: interferon \u03b3 release assays for tuberculosis. Arch Dis Child Educ Pract Ed 2013;98:99\u2013105.","journal-title":"Arch Dis Child Educ Pract Ed"},{"key":"50_CR11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1542-3565(04)00060-6","volume":"2","author":"WS Mow","year":"2004","unstructured":"Mow WS, Abreu-Martin MT, Papadakis KA, Pitchon HE, Targan SR, Vasiliauskas EA. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2004;2:309\u2013313.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"50_CR12","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.3899\/jrheum.130303","volume":"40","author":"F Costantino","year":"2013","unstructured":"Costantino F, de Carvalho Bittencourt M, Rat AC, Loeuille D, Dintinger H, Bene MC, et al. Screening for latent tuberculosis infection in patients with chronic inflammatory arthritis: discrepancies between tuberculin skin test and interferon-\u03b3 release assay results. J Rheumatol 2013;40:1986\u20131993.","journal-title":"J Rheumatol"},{"key":"50_CR13","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1111\/j.1523-1755.2004.00586.x","volume":"65","author":"M Sester","year":"2004","unstructured":"Sester M, Sester U, Clauer P, Heine G, Mack U, Moll T, et al. Tuberculin skin testing underestimates a high prevalence of latent tuberculosis infection in hemodialysis patients. Kidney Int 2004;65:1826\u20131834.","journal-title":"Kidney Int"},{"key":"50_CR14","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1093\/rheumatology\/kem351","volume":"47","author":"R Dinser","year":"2008","unstructured":"Dinser R, Fousse M, Sester U, Albrecht K, Singh M, Kohler H, et al. Evaluation of latent tuberculosis infection in patients with inflammatory arthropathies before treatment with TNF-alpha blocking drugs using a novel flow-cytometric interferongamma release assay. Rheumatology (Oxford) 2008;47:212\u2013218.","journal-title":"Rheumatology (Oxford)"},{"key":"50_CR15","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1378\/chest.08-2575","volume":"136","author":"L Richeldi","year":"2009","unstructured":"Richeldi L, Losi M, D\u2019Amico R, Luppi M, Ferrari A, Mussini C, et al. Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest 2009;136:198\u2013204.","journal-title":"Chest"},{"key":"50_CR16","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1128\/jb.178.5.1274-1282.1996","volume":"178","author":"GG Mahairas","year":"1996","unstructured":"Mahairas GG, Sabo PJ, Hickey MJ, Singh DC, Stover CK. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol 1996;178:1274\u20131282.","journal-title":"J Bacteriol"},{"key":"50_CR17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1128\/IAI.64.1.16-22.1996","volume":"64","author":"M Harboe","year":"1996","unstructured":"Harboe M, Oettinger T, Wiker HG, Rosenkrands I, Andersen P. Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG. Infect Immun 1996;64:16\u201322.","journal-title":"Infect Immun"},{"key":"50_CR18","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1309\/LMCQLO8PG0IZ5APX","volume":"46","author":"I Pavic","year":"2015","unstructured":"Pavic I, Katalinic-Jankovic V, Cepin-Bogovic J, Resic A, Dodig S. Discordance between tuberculin skin test and interferon-\u03b3 release assay in children younger than 5 years who have been vaccinated with Bacillus Calmette-Guerin. Lab Med 2015;46:200\u2013206.","journal-title":"Lab Med"},{"key":"50_CR19","doi-asserted-by":"publisher","first-page":"e0138952","DOI":"10.1371\/journal.pone.0138952","volume":"10","author":"M Sali","year":"2015","unstructured":"Sali M, Buonsenso D, Goletti D, D\u2019Alfonso P, Zumbo A, Fadda G, et al. Accuracy of QuantiFERON-TB Gold test for tuberculosis diagnosis in children. PLoS One 2015;10: e0138952.","journal-title":"PLoS One"},{"key":"50_CR20","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/INF.0b013e3181c4822f","volume":"29","author":"TG Connell","year":"2010","unstructured":"Connell TG, Tebruegge M, Ritz N, Bryant PA, Leslie D, Curtis N. Indeterminate interferon-gamma release assay results in children. Pediatr Infect Dis J 2010;29:285\u2013286.","journal-title":"Pediatr Infect Dis J"},{"key":"50_CR21","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1097\/INF.0b013e3181a16394","volume":"28","author":"T Haustein","year":"2009","unstructured":"Haustein T, Ridout DA, Hartley JC, Thaker U, Shingadia D, Klein NJ, et al. The likelihood of an indeterminate test result from a whole-blood interferon-gamma release assay for the diagnosis of Mycobacterium tuberculosis infection in children correlates with age and immune status. Pediatr Infect Dis J 2009;28:669\u2013673.","journal-title":"Pediatr Infect Dis J"},{"key":"50_CR22","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1128\/JCM.01320-08","volume":"47","author":"E Bruzzese","year":"2009","unstructured":"Bruzzese E, Bocchino M, Assante LR, Alessio M, Bellofiore B, Bruzzese D, et al. Gamma interferon release assays for diagnosis of tuberculosis infection in immune-compromised children in a country in which the prevalence of tuberculosis is low. J Clin Microbiol 2009;47:2355\u20132357.","journal-title":"J Clin Microbiol"},{"key":"50_CR23","first-page":"1","volume":"59","author":"GH Mazurek","year":"2010","unstructured":"Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection-United States, 2010. MMWR Recomm Rep 2010;59:1\u201325.","journal-title":"MMWR Recomm Rep"},{"key":"50_CR24","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1183\/09031936.00149212","volume":"42","author":"W Hoefsloot","year":"2013","unstructured":"Hoefsloot W, van Ingen J, Andrejak C, Angeby K, Bauriaud R, Bemer P, et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J 2013;42:1604\u20131613.","journal-title":"Eur Respir J"},{"key":"50_CR25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/0962-8479(94)90003-5","volume":"75","author":"Criteria for discontinuation of vaccination programmes using Bacille Calmette-Guerin BCG in countries with a low prevalence of tuberculosis.","year":"1994","unstructured":"Criteria for discontinuation of vaccination programmes using Bacille Calmette-Guerin (BCG) in countries with a low prevalence of tuberculosis. A statement of the International Union Against Tuberculosis and Lung Disease. Tuber Lung Dis 1994;75:179\u2013180.","journal-title":"Tuber Lung Dis"},{"key":"50_CR26","first-page":"1","volume":"49","author":"Targeted tuberculin testingtreatment of latent tuberculosis infection.","year":"2000","unstructured":"Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000;49:1\u201351.","journal-title":"MMWR Recomm Rep"},{"key":"50_CR27","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.5588\/ijtld.14.0282","volume":"18","author":"F Gabriele","year":"2014","unstructured":"Gabriele F, Katragkou A, Roilides E. BCG vaccination policy in Greece: time for another review? Int J Tuberc Lung Dis 2014;18:1258.","journal-title":"Int J Tuberc Lung Dis"},{"key":"50_CR28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/ard.2008.101857","volume":"69","author":"J Martin","year":"2010","unstructured":"Martin J, Walsh C, Gibbs A, McDonnell T, Fearon U, Keane J, et al. Comparison of interferon {gamma} release assays and conventional screening tests before tumour necrosis factor {alpha} blockade in patients with inflammatory arthritis. Ann Rheum Dis 2010;69:181\u2013185.","journal-title":"Ann Rheum Dis"},{"key":"50_CR29","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1136\/ard.2007.070789","volume":"67","author":"G Matulis","year":"2008","unstructured":"Matulis G, Juni P, Villiger PM, Gadola SD. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigenspecific interferon gamma assay. Ann Rheum Dis 2008;67:84\u201390.","journal-title":"Ann Rheum Dis"},{"key":"50_CR30","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s10067-010-1550-z","volume":"30","author":"AJ Kwakernaak","year":"2011","unstructured":"Kwakernaak AJ, Houtman PM, Weel JF, Spoorenberg JP, Jansen TL. A comparison of an interferon-gamma release assay and tuberculin skin test in refractory inflammatory disease patients screened for latent tuberculosis prior to the initiation of a first tumor necrosis factor \u03b1 inhibitor. Clin Rheumatol 2011;30:505\u2013510.","journal-title":"Clin Rheumatol"},{"key":"50_CR31","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1183\/09031936.00122109","volume":"35","author":"B Lange","year":"2010","unstructured":"Lange B, Vavra M, Kern WV, Wagner D. Indeterminate results of a tuberculosis-specific interferon-gamma release assay in immunocompromised patients. Eur Respir J 2010;35:1179\u20131182.","journal-title":"Eur Respir J"},{"key":"50_CR32","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1183\/09031936.00040007","volume":"30","author":"Y Kobashi","year":"2007","unstructured":"Kobashi Y, Mouri K, Obase Y, Fukuda M, Miyashita N, Oka M. Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients. Eur Respir J 2007;30:945\u2013950.","journal-title":"Eur Respir J"},{"key":"50_CR33","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1164\/rccm.200502-196OC","volume":"172","author":"G Ferrara","year":"2005","unstructured":"Ferrara G, Losi M, Meacci M, Meccugni B, Piro R, Roversi P, et al. Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection. Am J Respir Crit Care Med 2005;172:631\u2013635.","journal-title":"Am J Respir Crit Care Med"},{"key":"50_CR34","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1183\/09031936.00013409","volume":"34","author":"U Sester","year":"2009","unstructured":"Sester U, Wilkens H, van Bentum K, Singh M, Sybrecht GW, Schafers HJ, et al. Impaired detection of Mycobacterium tuberculosis immunity in patients using high levels of immunosuppressive drugs. Eur Respir J 2009;34:702\u2013710.","journal-title":"Eur Respir J"},{"key":"50_CR35","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1002\/ibd.21605","volume":"17","author":"E Belard","year":"2011","unstructured":"Belard E, Semb S, Ruhwald M, Werlinrud AM, Soborg B, Jensen FK, et al. Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis 2011;17:2340\u20132349.","journal-title":"Inflamm Bowel Dis"},{"key":"50_CR36","first-page":"417","volume":"12","author":"AM Mandalakas","year":"2008","unstructured":"Mandalakas AM, Hesseling AC, Chegou NN, Kirchner HL, Zhu X, Marais BJ, et al. High level of discordant IGRA results in HIV-infected adults and children. Int J Tuberc Lung Dis 2008;12:417\u2013423.","journal-title":"Int J Tuberc Lung Dis"},{"key":"50_CR37","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s10067-011-1724-3","volume":"30","author":"SA Camlar","year":"2011","unstructured":"Camlar SA, Makay B, Appak O, Appak YC, Esen N, Gunay T, et al. Performance of tuberculin skin test and interferon gamma assay for the diagnosis of latent tuberculosis infection in juvenile idiopathic arthritis. Clin Rheumatol 2011;30:1189\u20131193.","journal-title":"Clin Rheumatol"},{"key":"50_CR38","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1007\/s10067-012-2049-6","volume":"31","author":"R Scrivo","year":"2012","unstructured":"Scrivo R, Sauzullo I, Mengoni F, Iaiani G, Vestri AR, Priori R, et al. Serial interferon-\u03b3 release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents. Clin Rheumatol 2012;31:1567\u20131575.","journal-title":"Clin Rheumatol"},{"key":"50_CR39","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.3899\/jrheum.090268","volume":"36","author":"N Inanc","year":"2009","unstructured":"Inanc N, Aydin SZ, Karakurt S, Atagunduz P, Yavuz S, Direskeneli H. Agreement between Quantiferon-TB gold test and tuberculin skin test in the identification of latent tuberculosis infection in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 2009;36:2675\u20132681.","journal-title":"J Rheumatol"},{"key":"50_CR40","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1136\/ard.2009.113829","volume":"69","author":"S Kleinert","year":"2010","unstructured":"Kleinert S, Kurzai O, Elias J, Marten K, Engelke C, Feuchtenberger M, et al. Comparison of two interferon-gamma release assays and tuberculin skin test for detecting latent tuberculosis in patients with immune-mediated inflammatory diseases. Ann Rheum Dis 2010;69:782\u2013784.","journal-title":"Ann Rheum Dis"},{"key":"50_CR41","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1002\/ibd.21602","volume":"17","author":"E Tedesco Del","year":"2011","unstructured":"Del Tedesco E, Roblin X, Laharie D, Peyrin Biroulet L. Does anti-TNF therapy influence the performance of mycobacterium tuberculosis antigen-specific interferon-gamma assays? A French multicenter experience. Inflamm Bowel Dis 2011;17:1824.","journal-title":"Inflamm Bowel Dis"},{"key":"50_CR42","doi-asserted-by":"publisher","first-page":"5217","DOI":"10.4049\/jimmunol.167.9.5217","volume":"167","author":"AA Pathan","year":"2001","unstructured":"Pathan AA, Wilkinson KA, Klenerman P, McShane H, Davidson RN, Pasvol G, et al. Direct ex vivo analysis of antigen-specific IFN-\u03b3-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J Immunol 2001;167:5217\u20135225.","journal-title":"J Immunol"},{"key":"50_CR43","volume-title":"Arthritis Res Ther","author":"H Hamdi","year":"2006","unstructured":"Hamdi H, Mariette X, Godot V, Weldingh K, Hamid AM, Prejean MV, et al. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 2006;8:R114."},{"key":"50_CR44","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1086\/505430","volume":"194","author":"OY Saliu","year":"2006","unstructured":"Saliu OY, Sofer C, Stein DS, Schwander SK, Wallis RS. Tumornecrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 2006;194:486\u2013492.","journal-title":"J Infect Dis"},{"key":"50_CR45","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/1756-185X.12708","volume":"19","author":"F Cantini","year":"2016","unstructured":"Cantini F, Lubrano E, Marchesoni A, Mathieu A, Olivieri I, Salvarani C, et al. Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey. Int J Rheum Dis 2016;19:799\u2013805.","journal-title":"Int J Rheum Dis"},{"key":"50_CR46","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1136\/ard.60.2.133","volume":"60","author":"L Berg","year":"2001","unstructured":"Berg L, Lampa J, Rogberg S, van Vollenhoven R, Klareskog L. Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors. Ann Rheum Dis 2001;60:133\u2013139.","journal-title":"Ann Rheum Dis"},{"key":"50_CR47","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/j.imbio.2011.07.006","volume":"216","author":"O Aravena","year":"2011","unstructured":"Aravena O, Pesce B, Soto L, Orrego N, Sabugo F, Wurmann P, et al. Anti-TNF therapy in patients with rheumatoid arthritis decreases Th1 and Th17 cell populations and expands IFN-\u03b3-producing NK cell and regulatory T cell subsets. Immunobiology 2011;216:1256\u20131263.","journal-title":"Immunobiology"}],"container-title":["World Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12519-017-0050-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-017-0050-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-017-0050-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T18:46:03Z","timestamp":1602355563000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12519-017-0050-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,22]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["50"],"URL":"https:\/\/doi.org\/10.1007\/s12519-017-0050-5","relation":{},"ISSN":["1708-8569","1867-0687"],"issn-type":[{"value":"1708-8569","type":"print"},{"value":"1867-0687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,22]]}}}